Bacteria: Gram-negative

Enterobacter cloacae complex

General medical information for education only, not medical advice. Treatment considerations summarize published guidance at drug-class level; therapy is chosen by the treating clinician using susceptibility results, local resistance patterns and current guidelines.

Overview

Gram-negative rods common in healthcare settings, notable for inducible AmpC beta-lactamase.

Infections

Urinary tract, respiratory, bloodstream, surgical-site and device-associated infection.

Signs and symptoms

Bloodstream infection, often linked to an intravenous catheter: fever and chills. Urinary infection, often in catheterized patients: fever and flank or suprapubic pain. Pneumonia in ventilated patients: fever, increased secretions and falling oxygen levels. Surgical-site infection: redness, drainage and wound breakdown.

Antibiotic and antimicrobial resistance

Chromosomal inducible AmpC (AmpC); may also acquire ESBL (ESBL genes) or carbapenemase genes (carbapenemases).

Treatment considerations

Guided by susceptibility testing; avoid relying on third-generation cephalosporins for serious infection.

Enterobacter cloacae colonies on an agar plate
Enterobacter cloacae colonies on tryptic soy agar. CDC Public Health Image Library; public domain. Image source
Gram-negative rods, schematic
Gram-negative rods. Schematic, not to scale; InnovexLab.

Sources

  1. CDC. Healthcare-associated infections: diseases and organisms.
  2. CDC. ESBL-producing Enterobacterales.
  3. CDC. Carbapenem-resistant Enterobacterales (CRE).
  4. IDSA. Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.
  5. IDSA. Complicated Urinary Tract Infections guideline.

Sources accessed November 2026. Links open external sites that InnovexLab does not control.

Medical disclaimer

This page is general educational information summarized from published public-health and professional-society guidance. It is not medical advice, a diagnosis or a treatment recommendation, and reading it does not create a clinician–patient relationship with InnovexLab. Decisions about testing, diagnosis and treatment belong to the treating clinician, using the patient’s history and examination, laboratory and susceptibility results, local resistance patterns and current guidelines. Guidance changes over time; consult the original sources for the latest version. InnovexLab provides this information as is and does not warrant that it is complete or current.

Patients with questions about their health should contact their own healthcare provider. In an emergency, call 911.

Sources, image credits and editorial policy

Discuss a testing program with InnovexLab

Review the panel that fits your patients, its specimen requirements, and how results and billing work.